Bio-Rad Laboratories Inc. (BIO.B)
NYSE: BIO.BHealthcareMedical DevicesUSD
Market open · Delayed 15 min · as of Aug 20, 10:24 AM ET
BIO.B stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.76B
- P/E (TTM)
- 46.27
- EPS (TTM)
- $7.89
- Dividend yield
- None
- 52-week range
- 244.54 – 365.08
- Day range
- 365.08 – 365.08
- Volume / Avg
- 8 / 6
- Beta
- —
- Shares outstanding
- 5.06M
- Next earnings
- Nov 4, 2026
52-week range
BIO.B stock today
Bio-Rad Laboratories (BIO.B) last traded at $365.08 on Aug 20. The stock is trading at or near its 52-week high of $365.08, set on Aug 20, 2026, 49.3% above the 52-week low of $244.54. BIO.B is up 17.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 28.2%.
Bio-Rad Laboratories trades at 46.3x its trailing twelve-month earnings per share of $7.89. Bio-Rad Laboratories's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Bio-Rad Laboratories
Company profileBio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. Norman D. Schwartz
- Headquarters
- Hercules, CA
- Employees
- 7,450
- Website
- bio-rad.com
Financial highlights
Full financialsIn fiscal 2025, Bio-Rad Laboratories generated $2.58 billion in revenue, up 0.7% from fiscal 2024. Net income was $759.9 million, for a net margin of 29.4% versus a median of -23.9% in the prior 5 years. Gross margin was 51.9% (down from 53.7%) and operating margin 1.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B |
| Growth | +0.65% | -3.92% | -4.67% | -4.12% | +14.81% |
| Net income | $759.90M | $-1.84B | $-637.30M | $-3.63B | $4.25B |
| EPS (diluted) | $27.85 | $-65.36 | $-21.82 | $-121.79 | $140.83 |
Earnings
Earnings history- Next report
- Nov 4, 2026
- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $13.85 vs —
Indexes, lists and sector
Appears in lists
Largest Healthcare stocks
Bio-Rad Laboratories stock FAQ
What is Bio-Rad Laboratories's stock price today?
BIO.B last traded at $365.08 as of Aug 20, 10:24 AM EDT, up 0.00% on the day. Prices are delayed at least 15 minutes.
Does Bio-Rad Laboratories pay a dividend?
No. Bio-Rad Laboratories does not currently pay a regular cash dividend.
When is Bio-Rad Laboratories's next earnings date?
Bio-Rad Laboratories is expected to report earnings on Wednesday, November 4, 2026.
What is BIO.B's P/E ratio?
BIO.B trades at a trailing P/E ratio of 46.27.
Who is Bio-Rad Laboratories's CEO?
Mr. Norman D. Schwartz is the chief executive officer of Bio-Rad Laboratories Inc., which has about 7,450 employees.
Has BIO.B ever split its stock?
Yes. The most recent BIO.B stock split was a 2-for-1 split on Mar 8, 2002.
What is the BIO.B 52-week high?
The 52-week high for BIO.B is $365.08 and the 52-week low is $244.54. The stock is currently 0.0% below its high.